Who are Mesalazine plus Lactobacillus casei's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mesalazine-plus-lactobacillus-casei.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Mesalazine plus Lactobacillus casei — Competitive Intelligence Brief

Mesalazine plus Lactobacillus casei (Mesalazine plus Lactobacillus casei) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-inflammatory agent plus probiotic combination. Area: Gastroenterology.

marketed Anti-inflammatory agent plus probiotic combination Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Mesalazine plus Lactobacillus casei (Mesalazine plus Lactobacillus casei) — Hospital Cristo Re. Mesalazine reduces intestinal inflammation while Lactobacillus casei provides beneficial bacteria to restore and maintain a healthy gut microbiome.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mesalazine plus Lactobacillus casei TARGET	Mesalazine plus Lactobacillus casei	Hospital Cristo Re	marketed	Anti-inflammatory agent plus probiotic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-inflammatory agent plus probiotic combination class)

Hospital Cristo Re · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mesalazine plus Lactobacillus casei — Competitive Intelligence Brief. https://druglandscape.com/ci/mesalazine-plus-lactobacillus-casei. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab